For the year ending 2025-12-31, TVTX made $1,093,075K in revenue. -$26,655K in net income. Net profit margin of -2.44%.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Total revenue-License | 80,268 | |||
| Total revenue-Product | 410,460 | |||
| Research and development | 206,011 | |||
| Selling, general and administrative | 337,202 | |||
| Restructuring | 0 | |||
| In-process research and development | 0 | |||
| Product | 5,813 | |||
| License | 4,526 | |||
| Cost of goods sold | 10,339 | |||
| Total operating expenses | 553,552 | |||
| Operating loss | -62,824 | |||
| Interest income | 12,721 | |||
| Interest expense | 10,748 | |||
| Other income (expense), net | 11,578 | |||
| Total other income, net | 13,551 | |||
| Loss from continuing operations before income tax provision | -49,273 | |||
| Income tax provision on continuing operations | 988 | |||
| Loss from continuing operations, net of tax | -50,261 | |||
| Income (loss) from discontinued operations, net of tax | 24,715 | |||
| Net loss | -25,546 | |||
| Unrealized (loss) gain on marketable debt securities | -383 | |||
| Unrealized gain (loss) on defined benefit pension plan | -219 | |||
| Foreign currency translation (loss) gain | -945 | |||
| Comprehensive loss | -26,655 | |||
| Net loss per common share, basic (in dollars per share) | -0.29 | |||
| Net loss per common share, diluted (in dollars per share) | -0.29 | |||
| Weighted average common shares outstanding, basic (in shares) | 89,211,813 | |||
| Weighted average common shares outstanding, diluted (in shares) | 89,211,813 | |||
Travere Therapeutics, Inc. (TVTX)
Travere Therapeutics, Inc. (TVTX)